HVO vs. PRTC, OXB, HZD, FARN, VRP, ARIX, 4BB, AVCT, CIR, and BVXP
Should you be buying hVIVO stock or one of its competitors? The main competitors of hVIVO include PureTech Health (PRTC), Oxford Biomedica (OXB), Horizon Discovery Group plc (HZD.L) (HZD), Faron Pharmaceuticals Oy (FARN), Verona Pharma plc (VRP.L) (VRP), Arix Bioscience (ARIX), 4basebio (4BB), Avacta Group (AVCT), Circassia Group (CIR), and Bioventix (BVXP). These companies are all part of the "biotechnology" industry.
hVIVO vs.
hVIVO (LON:HVO) and PureTech Health (LON:PRTC) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, community ranking, analyst recommendations, media sentiment, risk, profitability, earnings, valuation and dividends.
In the previous week, PureTech Health had 1 more articles in the media than hVIVO. MarketBeat recorded 1 mentions for PureTech Health and 0 mentions for hVIVO. hVIVO's average media sentiment score of 0.00 beat PureTech Health's score of -1.10 indicating that hVIVO is being referred to more favorably in the media.
34.9% of hVIVO shares are held by institutional investors. Comparatively, 79.9% of PureTech Health shares are held by institutional investors. 14.0% of hVIVO shares are held by company insiders. Comparatively, 15.9% of PureTech Health shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
hVIVO has a beta of 0.97, suggesting that its stock price is 3% less volatile than the S&P 500. Comparatively, PureTech Health has a beta of 1.02, suggesting that its stock price is 2% more volatile than the S&P 500.
hVIVO has higher revenue and earnings than PureTech Health. PureTech Health is trading at a lower price-to-earnings ratio than hVIVO, indicating that it is currently the more affordable of the two stocks.
PureTech Health received 407 more outperform votes than hVIVO when rated by MarketBeat users. Likewise, 86.60% of users gave PureTech Health an outperform vote while only 69.89% of users gave hVIVO an outperform vote.
PureTech Health has a consensus price target of GBX 455, suggesting a potential upside of 220.42%. Given PureTech Health's stronger consensus rating and higher probable upside, analysts clearly believe PureTech Health is more favorable than hVIVO.
hVIVO has a net margin of 25.96% compared to PureTech Health's net margin of -17,620.94%. hVIVO's return on equity of 47.93% beat PureTech Health's return on equity.
Summary
PureTech Health beats hVIVO on 10 of the 18 factors compared between the two stocks.
Get hVIVO News Delivered to You Automatically
Sign up to receive the latest news and ratings for HVO and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
This page (LON:HVO) was last updated on 4/2/2025 by MarketBeat.com Staff
Buy HVO Stock Free HVO Stock Alerts